Takeda’s Zasocitinib Shows Strong Efficacy in Psoriasis Trials — Takeda Pharmaceutical Company Limited

Event summary

Takeda’s zasocitinib achieved rapid and durable skin clearance in Phase 3 trials for moderate-to-severe plaque psoriasis.
71.4% and 69.2% of patients treated with zasocitinib achieved clear or almost clear skin at week 16, compared to placebo (10.7%, 12.6%) and apremilast (32.1%, 29.7%).
Zasocitinib demonstrated a favorable safety profile consistent with Phase 2b studies.
Takeda plans to submit a New Drug Application starting in fiscal year 2026.

The big picture

Takeda’s zasocitinib represents a potential paradigm shift in psoriasis care, offering an oral alternative to injectable treatments. The positive Phase 3 results position zasocitinib as a strong contender in the immune-mediated inflammatory disease market, which is valued at billions globally. The success of this drug could also influence Takeda’s broader pipeline strategy in other inflammatory conditions.

What we're watching

Regulatory Approval Timing: The pace at which Takeda secures regulatory approval for zasocitinib will determine its market entry and competitive positioning.
Market Differentiation: Whether zasocitinib can sustain its efficacy and safety advantages over existing treatments like apremilast and deucravacitinib.
Commercialization Strategy: How Takeda plans to market zasocitinib as a convenient once-daily oral treatment in a space dominated by injectable therapies.